Clinical trial NCT04595825: CM-101 in PSC Patients -The SPRING Study
Official title: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial Evaluating the Safety and Efficacy of CM-101 in Subjects With Primary Sclerosing Cholangitis (The SPRING Study)
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE2
Conditions: Primary Sclerosing Cholangitis
Keywords: Anti-fibrotic
Lead sponsor: ChemomAb Ltd.
Sponsor class: INDUSTRY
First posted: 2020-10-22
Enrollment: 68
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is designed to assess the safety, tolerability and activity of the anti-human CCL24 monoclonal antibody CM-101 in adult subjects with Primary Sclerosing Cholangitis (PSC). At least 68 subjects at approximately 50 sites will be randomized to receive either CM-101 at doses of 10 mg/kg or 20 mg/kg or matching placebo.

Detailed description: This study will consist of a screening period, double-blind (DB) treatment period, open-label (OL) treatment period, and safety follow-up period. During the DB treatment period, subjects will receive 5 total dose administrations of study drug (investigational product - IP or placebo) once every 3 weeks (Q3W) for a coverage of 15 weeks. After completing the DB treatment period, subjects may elect to enroll in an OL treatment period. In the OL treatment period, subjects will receive a dose of IP Q3W for 11 administrations for a coverage of 33 weeks, resulting in a combined total coverage of up to 48 weeks.

Subjects who do not elect to continue treatment in the OL dosing period will undergo an End of Treatment (EOT)-DB visit at Week 15 (Day 105), a Safety Follow-up Call at Week 21 (Day 147), and an End of Study (EOS) visit at Week 27. Eligible subjects who continue treatment in the OL treatment period will receive CM-101 at either a 10 mg/kg or 20 mg/kg dose commencing at Week 15 (OL Treatment 1), and the subjects will undergo an EOT-OL visit at Week 48 (Day 336), a Safety Follow-up Call at Week 54 (Day 378), and an EOS visit at Week 60 (Day 420).

Eligibility criteria: Inclusion Criteria:

* Subjects with diagnosis of large duct PSC of more than 24 weeks' duration
* Subjects that have no significant clinical concern for cholangiocarcinoma based on clinical, laboratory or imaging findings
* Subjects with serum Alkaline phosphatase (ALP) greater than 1.5 × Upper limit of normal (ULN) in Screening blood tests.
* Subjects receiving Ursodeoxycholic acid (UDCA) must receive a stable dose for ≥12 weeks prior to Screening
* Subjects with concomitant inflammatory bowel disease (IBD) is allowed but not required, and must meet the following stability criteria.

Subjects with ulcerative colitis: Must be either in remission or have mild disease. Must have recent colonoscopy with biopsy confirming no dysplasia or colorectal cancer or history of colectomy.

* Subjects with Crohn's Disease must be in remission as defined by a Crohn's Disease Activity Index (CDAI) \< 150.
* Subjects receiving concomitant medication for IBD, dose must be stable ≥12 weeks prior to screening and dose should remain stable during DB portion of the study

  * Subjects receiving concomitant medication for their PSC must be on stable therapy ≥12 weeks prior to randomization and plan to remain on that stable dose during the DB portion of the study
  * Female subjects of childbearing potential, must have a negative serum pregnancy test prior to starting study treatment and must have agree to highly effective method of contraception from the Screening Visit throughout the study period including 18 weeks post last dose
  * Male subjects, if not vasectomized, must agree to use barrier contraception from screening through to study completion and for 90 days from the last dose of study drug

Exclusion Criteria:

* Subjects with presence of documented secondary sclerosing cholangitis on prior clinical investigations
* Subjects with presence of competing etiology of liver disease.
* Subjects with possible overlap syndrome with autoimmune hepatitis are excluded if the Investigator considers autoimmune hepatitis as the predominant liver injury
* Subjects with small duct PSC in the absence of large duct disease
* Subjects with percutaneous biliary drain or bile duct stent or subjects who had required biliary drainage within 12 weeks of Screening
* Subjects that have undergone prior biliary surgery other than those who at the time of screening are more than 6 weeks after cholecystectomy without surgical complications
* Subjects with evidence of liver cirrhosis, as determined by local transient elastography values of ≥ 14.4 kPa obtained during the Screening period. In case of a fibrosis staging discrepancy between a recent (≤ 12 months) liver biopsy staging and the transient elastography results, eligibility will be based on the liver biopsy staging.
* History of cirrhosis and/or hepatic impairment (Child-Pugh classes A, B and C), and/or hepatic decompensation including ascites, encephalopathy, or variceal bleeding
* Subjects who have undergone or are planned for liver transplantation or with current model of end stage liver disease
* Subjects with Aspartate aminotransferase (AST) or Alanine aminotransferase (ALT) values \> 5 × ULN as determined at Screening
* Subjects who show 'clinically significant' lab changes at Screening
* Subjects with serum total bilirubin values \> 3 × ULN at Screening
* Subjects with known Gilbert's syndrome or a history of elevations in unconjugated (indirect) bilirubin \>ULN
* Subjects with international normalized ratio (INR) \>1.5 which does not correct on vitamin K replacement, in the absence of anticoagulants
* Subjects with serum creatinine \> 1.4 mg/dL (123 μmol/L) and/or a platelet count \< 100 × 109 /L
* Subjects with history of cholangiocarcinoma or a high clinical suspicion for cholangiocarcinoma
* Subjects with elevated cancer antigen 19-9 (Ca 19-9) value (\> 129 U/mL) within 12 months prior to Screening unless Ca 19-9 levels have been stable and clinical evaluation and repeated Magnetic resonance imaging (MRI) within the same time period has not provided evidence of cholangiocarcinoma
* Subjects with a prior biliary stricture necessitating intervention should be stable for ≥ 24 weeks prior to randomization without intervention, or episode of cholangitis, and should show a low level of clinical suspicion of cholangiocarcinoma
* Subjects with current known portal hypertension with complications, including known gastric or large esophageal varices, poorly controlled or diuretic resistant ascites, history of variceal bleeds, or related therapeutic or prophylactic interventions
* Subjects with active malignancy (diagnosed and/or treated within 3 years of randomization), other than:

  * adequately treated non-metastatic basal cell skin cancer
  * squamous cell skin cancer that has been adequately treated and that has not recurred for at least 1 year prior to randomization
  * history of cervical carcinoma in situ that has been adequately treated and that has not recurred.
* Subjects with a 'clinically significant' (as judged by the Investigator) unexplained weight loss during the 24 weeks prior to randomization
* Subjects showing deleterious effects of alcohol abuse or that consume excessive amounts of alcohol
* Subjects with known or suspected acute cholangitis in the 90 days prior to randomization, including cholangitis treated with antibiotics within the 90 days
* Subjects experiencing flare in colitis activity within 90 days of randomization requiring intensification of therapy beyond baseline maintenance treatment or use of oral prednisone \> 10 mg/day (or equivalent), start or dose change of biologics ≤ 12 weeks before screening and or hospitalization for colitis within 90 days of randomization
* Subjects treated with or who are expected to begin treatment with fenofibrate or other fibrates or subjects who had a change in dose within 24 weeks of Screening, or subjects who are not planned to remain on a stable dose throughout the DB portion of the study
* Subjects that use any prohibited medication
* Subjects who have a known history of hypersensitivity reaction to CHO-derived antibodies, CM-101, or any of the formulation excipients
* Subjects with known chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection or that have positive hepatitis B surface antigen (HBSAg) at Screening
* Subjects with evidence of an active infection during the Screening period
* Subjects with any identified congenital or acquired immune-deficiency
* Subjects who have gone through major surgical procedure within 60 days of randomization or have had prior organ transplantation
* Subjects who have received a live/attenuated vaccine within 30 days of study randomization
* Female subjects who are pregnant or breast- feeding
* Subjects that have participated in an investigational trial of a drug or device either within 60 days of randomization; or where the study drug half-life is greater than 12 days, at least 5 half-lives need to have passed from the last dose of investigational drug prior to randomization
* Subjects with any other conditions, clinically significant disorders, or prior therapy that would make the subject unsuitable for the study or unable to comply with the dosing and study requirements

Primary outcomes:
measure: Safety-related endpoints - number of participants with treatment-emergent adverse events (TEAEs)
timeFrame: 15 week double-blind (DB) treatment period
Secondary outcomes:
measure: Safety-related endpoints - number of participants with abnormal vital sign changes
timeFrame: 48 week double-blind (DB) and open-label (OL) treatment periods
measure: Safety-related endpoints - number of participants with abnormal changes in clinical safety laboratory test results
timeFrame: 48 week double-blind (DB) and open-label (OL) treatment periods
measure: Safety-related endpoints - number of participants with infusion site reactions
timeFrame: 48 week double-blind (DB) and open-label (OL) treatment periods
measure: Alkaline phosphate (ALP) levels
timeFrame: Change from baseline through Week 15
measure: Enhanced Liver Fibrosis (ELF) score value
timeFrame: Change from baseline through Week 15
measure: ALP response rates
timeFrame: Change from baseline through Week 15
measure: Percent change in liver enzymes levels
timeFrame: Percent change from baseline through Week 15
measure: Change in liver fibrosis markers
timeFrame: Change from baseline through Week 15
measure: Elucidation of the serum Pharmacokinetics (PK) Profile - C0
timeFrame: Up to 60 weeks
measure: Elucidation of the serum Pharmacokinetics (PK) Profile - Cmax
timeFrame: Up to 60 weeks
measure: Elucidation of the serum Pharmacokinetics (PK) Profile - Tmax
timeFrame: Up to 60 weeks
measure: Elucidation of the serum Pharmacokinetics (PK) Profile - AUClast
timeFrame: Up to 60 weeks
measure: Elucidation of the serum Pharmacokinetics (PK) Profile - AUC∞
timeFrame: Up to 60 weeks
measure: Elucidation of the serum Pharmacokinetics (PK) Profile - λz
timeFrame: Up to 60 weeks
measure: Elucidation of the serum Pharmacokinetics (PK) Profile - t½
timeFrame: Up to 60 weeks
measure: Development of Anti-drug antibodies (ADAs)
timeFrame: 15 weeks
measure: Development of Anti-drug antibodies (ADAs)
timeFrame: 48 weeks
measure: Assessment of Pharmacodynamic (PD) parameters - Serum CCL24 levels
timeFrame: Up to 60 weeks
measure: Assessment of Pharmacodynamic (PD) parameters - Inflammatory marker levels of cytokines
timeFrame: Up to 60 weeks
measure: Assessment of Pharmacodynamic (PD) parameters - Inflammatory marker levels of interleukins
timeFrame: Up to 60 weeks
measure: Assessment of Pharmacodynamic (PD) parameters - Single cell ribonucleic acid sequencing from whole blood samples
timeFrame: Up to 60 weeks
measure: Assessment of Pharmacodynamic (PD) parameters - IgG4 levels
timeFrame: Up to 60 weeks
measure: Assessment of Pharmacodynamic (PD) parameters - IgG1 levels
timeFrame: Up to 60 weeks
Other outcomes:
Locations:
city: La Jolla
country: United States
facility: Scripps Clinic Torrey Pines - site P83
state: California
city: Sacramento
country: United States
facility: UC Davis Health System - Midtown Ambulatory Care Center - site P79
state: California
city: Chicago
country: United States
facility: Northwestern University - site P77
state: Illinois
city: Boston
country: United States
facility: Massachusetts General Hospital - site P95
state: Massachusetts
city: Boston
country: United States
facility: Harvard Medical School - Beth Israel Deaconess Medical Center (BIDMC) - Liver Center - site P81
state: Massachusetts
city: Germantown
country: United States
facility: Gastro One - GI Diagnostic and Therapeutic Endoscopy Center - 1310 Wolf Park - site P82
state: Tennessee
city: Dallas
country: United States
facility: Methodist Dallas Medical Center - site P72
state: Texas
city: Richmond
country: United States
facility: Virginia Commonwealth - site P94
state: Virginia
city: Frankfurt am Main
country: Germany
facility: Klinikum der Johann Wolfgang Goethe-Universitaet - site P42
city: Hamburg
country: Germany
facility: Universitätsklinikum Hamburg-Eppendorf (UKE) - site P47
city: Hannover
country: Germany
facility: Medizinische Hochschule Hannover (MHH) - site P41
city: Be'er Sheva
country: Israel
facility: Soroka MC - site P23
city: Be'er Ya'aqov
country: Israel
facility: Shamir Medical Center (Assaf Harofeh) - site P28
city: Haifa
country: Israel
facility: Carmel - site P27
city: Haifa
country: Israel
facility: Rambam MC - site P22
city: Jerusalem
country: Israel
facility: Hadassah Ein Kereme - site P21
city: Jerusalem
country: Israel
facility: Shaarei Tszedek Medical Center - site P29
city: Nahariya
country: Israel
facility: Galilee Medical Center - site P24
city: Nazareth
country: Israel
facility: EMMS Holy Family Nazareth Hospital - site P26
city: Tel Aviv
country: Israel
facility: Assuta Medical Center - site P31
city: Tel Aviv
country: Israel
facility: Tel-Aviv Sourasky Medical Center - site P30
city: Barcelona
country: Spain
facility: Hospital Clínic de Barcelona - site P67
city: Madrid
country: Spain
facility: Hospital Universitario Ramón y Cajal - site P61
city: Valencia
country: Spain
facility: Hospital Universitari i Politècnic La Fe - site P64
city: Zaragoza
country: Spain
facility: Hospital Universitario Miguel Servet - site P65
city: Leeds
country: United Kingdom
facility: Leeds Teaching Hospitals NHS Trust - site P08
state: WYK
city: Birmingham
country: United Kingdom
facility: University Hospitals Birmingham NHS Foundation Trust - site P05
city: Cambridge
country: United Kingdom
facility: Cambridge University Hospitals NHS Foundation Trust - Addenbrookes Hospital - site P09
city: Glasgow
country: United Kingdom
facility: NHS Greater Glasgow and Clyde - site P03
city: London
country: United Kingdom
facility: King's College Hospital NHS Foundation Trust - site P04
city: London
country: United Kingdom
facility: The Royal Free Hospital - site P01
city: Oxford
country: United Kingdom
facility: Oxford University Hospitals NHS Foundation Trust- site P11
city: Plymouth
country: United Kingdom
facility: Plymouth Hospitals NHS Trust - Derriford Hospital - site P07
Study officials:
affiliation: ChemomAb Ltd.
name: Matthew Frankel, MD
role: STUDY_DIRECTOR
References: